Augmedix, a company that say it turns natural clinician-patient conversation into medical documentation, announced on Wednesday, that Joe Marks, executive director of the Center for Machine Learning & Health at Carnegie Mellon University has been named as the company's new director.
Marks brings to the company extensive experience across such disciplines as artificial intelligence and human-in-the-loop automation. He has run the research labs at both Mitsubishi Electric and The Walt Disney Company. He has worked on DARPA-sponsored research projects for the US government, co-founded two start-ups, and has served as an advisor and consultant to the American Medical Association, all in addition to his current work at Carnegie Mellon. At Augmedix, Marks' official title will be independent director.
Manny Krakaris, chief executive officer at Augmedix, said, 'Augmedix is aggressively pursuing automation innovation in medical note documentation, data aggregation, and analysis. Joe Marks has an established record of pushing technical boundaries of artificial intelligence and machine learning, particularly within health care. We're delighted to have someone of Joe's stature join our team and apply his unique expertise to enhance our efforts in this area.'
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART